pioneer semaglutide Efficacy and safety of oral vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: 12, a double-blind, Phase IIIa, randomised trial | Diabetologia Change in body weight with

Food and Drug Administration (FDA): FDA Approves Zepbound (tirzepatide) for Chronic Weight Management The New England Journal of Medicine (NEJM): Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) The Lancet: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) Novo Nordisk: Ozempic (semaglutide) Prescribing Information Eli Lilly and Company: Zepbound (tirzepatide) Prescribing Information Obesity Medicine Association (OMA): Clinical Practice Guidelines for Chronic Weight Management

GLP-1 receptor agonists, however, have a very similar composition to GLP1 but are designed to resist breakdown by DPP-4 (Figure 2)

2) identified decreased (p 0.05 for all